Form D · Pharmaceuticals

Centaur Bio Inc.

Charlotte, NC · CIK 0001975017

Offering snapshot reported Sep 10, 2024 · SEC filing

Reported sold: $1M
Investors reported: 26
Minimum accepted: $7.5K
First sale: Mar 5, 2024

Fundraising history

Reported sold

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

Reported sold$471,000 → $1,000,000
Reported investors11 → 26
Minimum accepted$10,000 → $7,500

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Sep 10, 2024	Amendment	$1,000,000	$529,000vs Jul 30, 2024	26	SEC filing
Jul 30, 2024	Initial	$471,000	No comparison	11	SEC filing
Sep 7, 2023	Amendment	$500,000	$70,000vs Apr 27, 2023	5	SEC filing
Apr 27, 2023	Initial	$430,000	No comparison	4	SEC filing

Offering details

Securities: Debt, Option to acquire
Exemptions: 06b
Duration over one year: No
Business combination: No

Sales commissions: $100K
Finders' fees: $0
Form D file number: 021-520048

Sales compensation recipients

Scroll to see all columns →

Recipient	CRD	Associated broker-dealer
N/A	None	Laidlaw & Company (UK) Ltd. · CRD 119037

Source: Form D, filed Sep 10, 2024. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Michael James Roberts	Executive

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:

7805 Pemswood Street
Charlotte, NC, 28277